Regeneron Pharmaceuticals | Les Charges D'Exploitation

Operating Expenses Changement Date
AbbVie USD 11.11B 540M 2023-12
Agios Pharmaceuticals USD 113.38M 5.08M 2023-12
Alnylam Pharmaceuticals USD 556.12M 19.46M 2023-12
Amgen USD 6.93B 2.11B 2023-12
AstraZeneca USD 9.54B 578M 2023-09
Eli Lilly USD 6.97B 2.08B 2023-12
Gilead Sciences USD 5.5B 1.08B 2023-12
GlaxoSmithKline GBP 6.2B 1.16B 2023-09
Incyte USD 826.07M 121.75M 2023-12
Ionis Pharmaceuticals USD 303.83M 14.26M 2023-12
Kyowa Hakko Kirin JPY 69.82B 26.68B 2023-09
Moderna USD 2.8B 1.04B 2023-12
Neurocrine Biosciences USD 357.6M 21.5M 2023-09
Opthea USD 71.4M 7.6M 2023-06
Pfizer USD 20.8B 4.62B 2023-12
Regeneron Pharmaceuticals USD 2.46B 209.7M 2023-12
Roche Holding CHF 20.02B 5.04B 2023-06
Sarepta Therapeutics USD 380.16M 87.4M 2023-09
Teva Pharmaceutical Industries USD 3.5B 1.03B 2023-09
Ultragenyx Pharmaceutical USD 249.44M 6.29M 2023-12
United Therapeutics USD 354.6M 72.2M 2023-12
Vertex Pharmaceuticals USD 1.45B 21.4M 2023-09



Regeneron Pharmaceuticals Les Charges D'Exploitation - Les valeurs actuelles, des données historiques, des prévisions, des statistiques, des tableaux et le calendrier économique - Apr 2024.